A Phase IV, Prospective, Multicenter, Open Label, Uncontrolled, Non-interventional, Single Arm Study to Measure Treatment Satisfaction of Multiple Sclerosis (MS) Patients on Rebif® After Discontinuing Initial First-line Treatment
Phase of Trial: Phase IV
Latest Information Update: 13 Jun 2017
At a glance
- Drugs Interferon beta-1a (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms MESTRE-MS
- Sponsors Merck KGaA
- 07 Jun 2017 Planned End Date changed from 30 Sep 2018 to 28 Feb 2019.
- 07 Jun 2017 Planned primary completion date changed from 30 Sep 2018 to 28 Feb 2019.
- 10 May 2017 Status changed from not yet recruiting to recruiting.